<DOC>
	<DOCNO>NCT00115544</DOCNO>
	<brief_summary>The purpose study evaluate effect safety Stanate ( stannsoporfin ) infant risk exchange transfusion meet criterion protocol .</brief_summary>
	<brief_title>Safety Pharmacology Stanate</brief_title>
	<detailed_description>The present study evaluate relationship StanateÂ® dose , drug safety , efficacy non randomise sequential open label cohort design , 55 patient . Subjects term near term infant medium high risk hyperbilirubinemia TSB level approach threshold exchange transfusion . The first cohort begin dose stannsoporfin 0.75 mg/kg birth weight intramuscularly . The dose increase 1.5 mg/kg cohort 2 , saline give ( placebo ) cohort 3 . Safety evaluation consist hepatic , renal hematologic clinical laboratory test along serial physical examination . Long term follow patient age 6 plan .</detailed_description>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>Term nearterm healthy infant ( may 14 day age ) excessive hyperbilirubinemia risk exchange transfusion accord AAP guideline 2004 No parental consent Major know congenital anomaly Current use antibiotic , cardiorespiratory instability , abnormal renal function , hepatitis ( relate TORCH infection ) Phenobarbital use either child mother ( 30 day prior child 's birth )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>neonatal</keyword>
	<keyword>jaundice</keyword>
	<keyword>hyperbilirubinemia</keyword>
</DOC>